Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07552012 AC-201 Non-infectious posterior uveitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552012 clinical trial report covering AC-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07552077 Sirolimus Angiokeratoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552077 clinical trial report covering Sirolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123538 Acetaminophen Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600123538 clinical trial report covering Acetaminophen, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07552324 Polatuzumab Vedotin-Piiq Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552324 clinical trial report covering Polatuzumab Vedotin-Piiq, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07551804 Y-shape pegylated somatropin (Xiamen Amoytop Biotech) Growth hormone deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551804 clinical trial report covering Y-shape pegylated somatropin (Xiamen Amoytop Biotech), Phase 2, endpoints, sponsor, geography, readout timing an
Latest Hotspot
8 min read
CTR20261651 Ifinatamab deruxtecan Metastatic Esophageal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20261651 clinical trial report covering Ifinatamab deruxtecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07553065 NT-201 Urinary Incontinence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07553065 clinical trial report covering NT-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07551596 Botensilimab MSS/pMMR/MSI-L Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551596 clinical trial report covering Botensilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07552181 Clostridium butyricum M588(Miyarisan Pharma) Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552181 clinical trial report covering Clostridium butyricum M588(Miyarisan Pharma), Phase 2, endpoints, sponsor, geography, readout timing and develop
Latest Hotspot
8 min read
NCT07551635 Camibirstat Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551635 clinical trial report covering Camibirstat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07551583 Dacarbazine Classical Hodgkin's Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551583 clinical trial report covering Dacarbazine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261503 GFH-312 Primary Biliary Cholangitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20261503 clinical trial report covering GFH-312, Phase 2, endpoints, sponsor, geography, readout timing and development white space.